Citations

Clear

1526 citation(s) found for "Sun, Yu".

Resident Family and Medical Leave During the First Year of the American Board of Anesthesiology’s Extended Leave Policy
Dainer, Rupa J., Macario, Alex, Sun, Huaping , Warner, David O.

Mayo Clinic

Academic Medicine | September 29, 2021 | Volume: 96 | Issue: 10 | Pages: 1373-1373

10.1097/acm.0000000000004252 | PMID 34587138 Get It

IL-23 amplifies the epithelial-mesenchymal transition of mechanically conditioned alveolar epithelial cells in rheumatoid arthritis-associated interstitial lung disease through mTOR/S6 signaling
Zhang, Chujie , Wang, Shaohua , Lau, Jessica, Roden, Anja C. , Matteson, Eric L. , Tschumperlin, Daniel J. , Vassallo, Robert , Tschumperlin, Daniel J , Vassallo, Robert , Sun, Jie , Luo, Fengming

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | September 29, 2021 | Volume: 321 | Issue: 6 | Pages: L1006-L1022

10.1152/ajplung.00292.2021 | PMID 34585990 Get It

Epithelial-mesenchymal transition (EMT) creates an environment facilitating fibrosis following alveolar epithelial cell injury. IL-23 has important roles in chronic autoimmune conditions like rheumatoid arthritis (RA), but its role in the interstitial lung disease that affects patients with RA is unclear. This study aimed to determine the profibrogenic role of IL-23 on somatic alveolar type I (ATI) epithelial cells. Primary ATI cells were isolated from rats and cultured on plastic dishes for 1–3 wk. After prolonged culture (≥14 days) on rigid culture dishes, primary ATI cells gradually acquired a mesenchymal phenotype, identified by decreased expression of caveolin-1, and reorganization of F-actin cytoskeleton, indicating the initiation of EMT by matrix stiffness. To determine how IL-23 promotes EMT in vitro, transitioning ATI cells, cultured on a stiff substrate for ≥14 days were stimulated with IL-23. The EMT phenotype was significantly enhanced by IL-23, which upregulated α-smooth muscle actin (α-SMA), collagen I/III protein, and decreased caveolin-1. Furthermore, IL-23 significantly promoted cell invasion, as well as apoptotic resistance on transitioning ATI cells. Mechanistically, IL-23-induced EMT was mammalian target of rapamycin/ribosomal protein S6 (mTOR/S6) signaling dependent and reversible by rapamycin. Transcriptional sequencing analysis of human lung fibrosis biopsy tissue revealed key roles for IL-23 in rheumatoid arthritis-associated interstitial lung disease (RA-ILD). This result was further validated by significantly upregulated IL-23 expression at the mRNA level in RA-ILD lung sections. Notably, transitioning ATI epithelial cells were abundantly detected in RA-ILD tissue. Taken together, these data support a role for IL-23 in the pathogenesis of RA lung fibrosis by promoting EMT in alveolar epithelial cells through mTOR/S6 signaling.
Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases
Lin, Sinan , Mao, Ren , Qian, Chenchen , Wang, Jie , Bruining, David H. , Feagan, Brian G. , Chen, Minhu , Rieder, Florian , Rieder, Florian , Bettenworth, Dominik , Li, Jiannan , Jairath, Vipul

Mayo Clinic

Physiological Reviews | September 27, 2021 | Volume: 102 | Issue: 2 | Pages: 605-652

10.1152/physrev.00005.2021 | PMID 34569264 Get It

Intestinal fibrosis is considered an inevitable complication of Crohn’s disease (CD) that results in symptoms of obstruction and stricture formation. Endoscopic or surgical treatment is required to treat the majority of patients. Progress in the management of stricturing CD is hampered by the lack of effective antifibrotic therapy; however, this situation is likely to change because of recent advances in other fibrotic diseases of the lung, liver, and skin. In this review, we summarize data from randomized controlled trials (RCTs) of antifibrotic therapies in these conditions. Multiple compounds have been tested for antifibrotic effects in other organs. According to their mechanisms, they were categorized into growth factor modulators, inflammation modulators, 5-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, intracellular enzymes and kinases, renin-angiotensin system (RAS) modulators, and others. From our review of the results from the clinical trials and discussion of their implications in the gastrointestinal tract, we have identified several molecular candidates that could serve as potential therapies for intestinal fibrosis in CD.
Understanding diagnostic processes in emergency departments: a mixed methods case study protocol
Daniel, Michelle , Chandanabhumma, P. Paul , Fetters, Michael D. , Canvasser, Andrew B, Singh, Hardeep , Mahajan, Prashant , Pasupathy, Kalyan, Singh, Hardeep , Park, Sun Young , Seifert, Colleen M. , Wilson, Eric A. , Pasupathy, Kalyan S.

Mayo Clinic

BMJ Open | September 24, 2021 | Volume: 11 | Issue: 9 | Pages: e044194

10.1136/bmjopen-2020-044194 | PMID 34561251 Get It

Introduction Diagnostic processes in the emergency department (ED) involve multiple interactions among individuals who interface with information systems to access and record information. A better understanding of diagnostic processes is needed to mitigate errors. This paper describes a study protocol to map diagnostic processes in the ED as a foundation for developing future error mitigation strategies. Methods and analysis This study of an adult and a paediatric academic ED uses a prospective mixed methods case study design informed by an ED-specific diagnostic decision-making model (the modified ED-National Academies of Sciences, Engineering and Medicine (NASEM) model) and two cognitive theories (dual process theory and distributed cognition). Data sources include audio recordings of patient and care team interactions, electronic health record data, observer field notes and stakeholder interviews. Multiple qualitative analysis methods will be used to explore diagnostic processes in situ, including systems information flow, human–human and human–system interactions and contextual factors influencing cognition. The study has three parts. Part 1 involves prospective field observations of patients with undifferentiated symptoms at high risk for diagnostic error, where each patient is followed throughout the entire care delivery process. Part 2 involves observing individual care team providers over a 4-hour window to capture their diagnostic workflow, team coordination and communication across multiple patients. Part 3 uses interviews with key stakeholders to understand different perspectives on the diagnostic process, as well as perceived strengths and vulnerabilities, in order to enrich the ED-NASEM diagnostic model. Ethics and dissemination The University of Michigan Institutional Review Board approved this study, HUM00156261. This foundational work will help identify strengths and vulnerabilities in diagnostic processes. Further, it will inform the future development and testing of patient, provider and systems-level interventions for mitigating error and improving patient safety in these and other EDs. The work will be disseminated through journal publications and presentations at national and international meetings.
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
Menghrajani, Kamal , Gomez-Arteaga, Alexandra , Madero‐Marroquin, Rafael , Zhang, Mei‐Jie , Bo-Subait, Khalid, Sánchez, J. Ortiz, Wang, Hailin , Aljurf, Mahmoud , Assal, Amer , Bejanyan, Nelli , Bredeson, Christopher , Byrne, Michael , Castillo, Paul , Černý, Jan , Ciurea, Stefan O. , DeFilipp, Zachariah , Farhadfar, Nosha , Gadalla, Shahinaz M. , Ganguly, Siddhartha , Gowda, Lohith , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Kanakry, Christopher G. , Khimani, Farhad , Krem, Maxwell M. , Liu, Hongtao , Martino, Rodrigo , Michelis, Fotios V. , Nathan, Sunita , Rizzieri, David A. , Rowe, Jacob M. , Seo, Sachiko , Sharma, Akshay , Solh, Melhem , Üstün, Celalettin , Verdonck, Leo F. , Litzow, Mark R. , Weisdorf, Daniel J. , Zhang, Yanming , Tallman, Martin S. , Saber, Wael , Bacher, Ulrike , Bejanyan, Nelli , Bhatt, Vijaya Raj , Cerny, Jan , Chhabra, Saurabh , DeFilipp, Zachariah , Gadalla, Shahinaz M , Gale, Robert P , Hashmi, Shahrukh K , Hildebrandt, Gerhard C , Kansagra, Ankit , Krem, Maxwell M , Lazarus, Hillard M , Liu, Hongtao , Martino, Rodrigo , Michelis, Fotios V , Nishihori, Taiga , Olsson, Richard F , Reshef, Ran , Rizzieri, David A , Savani, Bipin N , Seo, Sachiko , Sharma, Akshay , Ustun, Celalettin , Hourigan, Christopher S , Sandmaier, Brenda M , Litzow, Mark R. , Weisdorf, Dan , Assal, Amer , Badawy, Sherif M. , Bhatt, Vijaya Raj , Chhabra, Saurabh , Gale, Robert Peter , Grunwald, Michael R. , Kansagra, Ankit , Lazarus, Hillard M. , Nishihori, Taiga , Olsson, Richard F. , Reshef, Ran , Savani, Bipin N. , Hourigan, Christopher S. , Kebriaei, Partow

Mayo Clinic

Blood Advances | September 22, 2021 | Volume: 6 | Issue: 3 | Pages: 828-847

10.1182/bloodadvances.2021004881 | PMID 34551064 Get It

Abstract Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. An adjusted multivariable analysis detected an increased risk of relapse for patients with KMT2A-rearranged or adverse-risk AML as compared to those with intermediate-risk disease (hazards ratio [HR], 1.27; P = .01; HR, 1.71; P < .001, respectively). Leukemia-free survival was similar for patients with KMT2A rearrangement or adverse risk (HR, 1.26; P = .002, and HR, 1.47; P < .001), as was overall survival (HR, 1.32; P < .001, and HR, 1.45; P < .001). No differences in outcome were detected when patients were stratified by KMT2A fusion partner. This study is the largest conducted to date on post-HCT outcomes in AML, with manually curated cytogenetics used for risk stratification. Our work demonstrates that risk classification at diagnosis remains predictive of post-HCT outcomes in AML. It also highlights the critical need to develop novel treatment strategies for patients with KMT2A-rearranged and adverse-risk disease.
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
Wieduwilt, Matthew J. , Metheny, Leland , Zhang, Mei‐Jie , Wang, Hailin , Estrada‐Merly, Noel, Marks, David I. , Al‐Homsi, A. Samer, Muffly, Lori , Chao, Nelson J. , Rizzieri, David A. , Gadalla, Shahinaz M. , Cairo, Mitchell S. , Gore, Steven D. , Patel, Sagar S. , Michelis, Fotios V. , Inamoto, Yoshihiro , Copelan, Edward A. , Palmisiano, Neil , Kharfan‐Dabaja, Mohamed A. , Ganguly, Siddhartha , Bredeson, Christopher , Ballen, Karen K. , Martino, Rodrigo , Wirk, Baldeep , Aljurf, Mahmoud , Bashey, Asad, Murthy, Hemant S. , Farhadfar, Nosha , Liu, Hongtao , Abdel‐Azim, Hisham , Solh, Melhem , Seftel, Matthew D. , Poel, Marjolein van der , Kamble, Rammurti T., Munker, Reinhold , Cahn, Jean‐Yves , Freytes, César O. , Krem, Maxwell M. , Winestone, Lena E. , Nathan, Sunita , Verdonck, Leo F. , Sharma, Akshay , Ringdén, Olle , Černý, Jan , Choe, Hannah , Seo, Sachiko , Baxter‐Lowe, Lee Ann , Hildebrandt, Gerhard , Litzow, Mark R. , Abid, Muhammad Bilal , Weisdorf, Daniel J. , Saber, Wael , Chao, Nelson , Rizzieri, David A , Gadalla, Shahinaz M , Bhatt, Vijaya Raj , Patel, Sagar , Michelis, Fotios V , Kharfan-Dabaja, Mohamed A , Savani, Bipin N , Martino, Rodrigo , Bacher, Ulrike , Liu, Hongtao , Waller, Edmund K , McGuirk, Joseph , Krem, Maxwell M , Winestone, Lena E , Olsson, Richard F , Sharma, Akshay , Ringden, Olov , Friend, Brian D , Cerny, Jan , Chhabra, Saurabh , Nishihori, Taiga , Seo, Sachiko , George, Biju , Baxter-Lowe, Lee Ann , Hildebrandt, Gerhard C , de Lima, Marcos , Litzow, Mark R. , Hourigan, Christopher S , Weisdorf, Dan , Murthy, Hemant S , Muffly, Lori , Abid, Muhammad Bilal , Gale, Robert Peter , Mussetti, Alberto , Bhatt, Vijaya Raj , Badawy, Sherif M. , Lazarus, Hillard M. , Díaz, Miguel Ángel , Cassaday, Ryan D. , Savani, Bipin N. , Yared, Jean A. , Aldoss, Ibrahim , Waller, Edmund K. , Grunwald, Michael R. , Liesveld, Jane L. , McGuirk, Joseph P. , Lee, Jong Wook , Gergis, Usama , Olsson, Richard F. , Chhabra, Saurabh , Nishihori, Taiga , Lima, Marcos de , Kebriaei, Partow , Hourigan, Christopher S.

Mayo Clinic

Blood Advances | September 21, 2021 | Volume: 6 | Issue: 1 | Pages: 339-357

10.1182/bloodadvances.2021004916 | PMID 34547770 Get It

Abstract The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.
DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer
Zou, Qi , Wang, Xiaolin , Ren, Donglin , Hu, Bang, Tang, Guannan , Zhang, Yu , Huang, Meijin , Pai, Rish K. , Win, Aung Ko , Yu, Huichuan , Luo, Yanxin , Yu, Huichuan , Luo, Yanxin , Win, Aung K , Buchanan, Daniel D. , Newcomb, Polly A. , Grady, William M.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | September 21, 2021 | Volume: 9 | Issue: 9 | Pages: e002671

10.1136/jitc-2021-002671 | PMID 34548385 Get It

Background Tumor-infiltrating lymphocytes (TILs), especially CD8+ TILs, can be used for predicting immunotherapy responsiveness and survival outcome. However, the evaluation of CD8+ TILs currently relies on histopathological methodology with high variability. We therefore aimed to develop a DNA methylation signature for CD8+ TILs (CD8+ MeTIL) that could evaluate immune response and prognosis in colorectal cancer (CRC). Methods A CD8+ MeTIL signature score was constructed by using CD8+ T cell-specific differentially methylated positions (DMPs) that were identified from Illumina EPIC methylation arrays. Immune cells, colon epithelial cells, and two CRC cohorts (n=282 and 335) were used to develop a PCR-based assay for quantitative analysis of DNA methylation at single-base resolution (QASM) to determine CD8 + MeTIL signature score. Results Three CD8+ T cell-specific DMPs were identified to construct the CD8+ MeTIL signature score, which showed a dramatic discriminability between CD8+ T cells and other cells. The QASM assay we developed for CD8+ MeTIL markers could measure CD8+ TILs distributions in a fully quantitative, accurate, and simple manner. The CD8+ MeTIL score determined by QASM assay showed a strong association with histopathology-based CD8+ TIL counts and a gene expression-based immune marker. Furthermore, the low CD8+ MeTIL score (enriched CD8+ TILs) was associated with MSI-H tumors and predicted better survival in CRC cohorts. Conclusions This study developed a quantitative DNA methylation-based signature that was reliable to evaluate CD8+ TILs and prognosis in CRC. This approach has the potential to be a tool for investigations on CD8+ TILs and a biomarker for therapeutic approaches, including immunotherapy.
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases
Ginès, Pere , Lammert, Frank , Graupera, Isabel , Serra‐Burriel, Miquel , Allen, Alina M. , Wong, Vincent Wai‐Sun , Thiele, Maja , Grgurević, Ivica , Augustín, Salvador , Tsochatzis, Emmanuel , Schattenberg, Jörn M. , Guha, Indra Neil , Martini, Andréa , Morillas, Rosa M. , Koning, Harry J. de , Pich, Judit, T., Ann , Díaz, M. A. Cruz , Newsome, Philip N. , Manns, Michael P. , Kamath, Patrick S. , Krag, Aleksander , Cervera, Marta , Allen, Alina M , Wong, Vincent Wai-Sun , de Knegt, Robert J , Tsochatzis, Emmanuel A , Schattenberg, Jörn M , Guha, Indra Neil , de Koning, Harry J , Fabrellas, Núria , Ma, Ann T , Newsome, Philip N , Krag, Aleksander , Gines, Pere , Thiele, Maja , Castera, Laurent , Hartmann, Phillipp , Caballería, Llorenç , Garcı́a-Retortillo, Montserrat , Fabrellas, Núria , Diaz, M. Alba, Roulot, Dominique M.

Mayo Clinic

Hepatology | September 19, 2021 | Volume: 75 | Issue: 1 | Pages: 219-228

10.1002/hep.32163 | PMID 34537988 Get It

Abstract Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non‐alcoholic fatty liver disease and alcohol‐related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. These modalities may be utilized for screening for liver fibrosis in at‐risk populations. Thus far, a limited number of population‐based studies using noninvasive tests in different areas of the world indicate that a significant percentage of subjects without known liver disease (around 5% in general populations and a higher rate −18% to 27%‐in populations with risk factors for liver disease) have significant undetected liver fibrosis or established cirrhosis. Larger international studies are required to show the harms and benefits before concluding that screening for liver fibrosis should be applied to populations at risk for chronic liver diseases. Screening for liver fibrosis has the potential for changing the current approach from diagnosing chronic liver diseases late when patients have already developed complications of cirrhosis to diagnosing liver fibrosis in asymptomatic subjects providing the opportunity of preventing disease progression.
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression
Investigators, The Parkinson Study Group SURE-PD3, Bluett, Brent , Togasaki, Daniel M., Mihaila, Dragos, Evatt, Marian L., Rezak, Michael, Jain, Samay , Schwarzschild, Michael A. , Ascherio, Alberto, Casaceli, Cindy, Kamp, Cornelia , Lungu, Codrin , Oakes, David , Rudolph, Alice, Shoulson, Ira , Scott, B.L. , Gauger, Lisa, Aldred, Jason , Bixby, Melissa, Ciccarello, Jill, Gunzler, Steven A. , Henchcliffe, Claire , Brodsky, Matthew , Keith, Kellie, Hauser, Robert A. , LeDoux, Mark S. , Hinson, Vanessa K. , Kumar, Rajeev , Hunter, Christine , Christine, Chadwick W. , Daley, Aaron, Leehey, Maureen A. , Marcaida, Joy Antonelle de, Hung, Albert Y. , Bwala, Grace, Simon, David K. , Simuni, Tanya , Poon, Cynthia , Schiess, Mya C. , Park, Ariane , Peterson, Carolyn, Criswell, Susan R. , Durphy, Jennifer, Shill, Holly A. , Mehta, Shyamal H. , Deik, Andres , Fang, John Y., Stover, Natividad , Zhang, Lin , Dewey, Richard B. , Gerald, Ashley, Boyd, James T. , Houston, Emily , Suski, Valerie, Mosovsky, Sherri, Cloud, Leslie , Shah, Binit, James, Raymond , Zauber, S. Elizabeth , Reich, Stephen G. , Langhammer, April, LaFaver, Kathrin , Kaminski, Patricia L. , Goudreau, John L. , Russell, Doozie, Houghton, David , LaRoche, Ashley , Thomas, Karen , McGraw, Martha, Mari, Zoltan, Blindauer, Karen, Rabin, Marcie, Kurlan, Roger, Morgan, John C. , Ainslie, Melissa, Bódis-Wollner, Iván , Waters, Cheryl , Ratel, Amber Servi, Beck, Christopher A. , Bolger, Patrick, Callahan, Katherine F., Crotty, Grace F. , Klements, David , Kostrzebski, Melissa, McMahon, Gearoid M. , Pothier, Lindsay , Hauser, Robert A , Simuni, Tanya , Investigators, The Parkinson Study Group SURE-PD3, Curhan, Gary C. , Fitzgerald, Rebecca, Macklin, Eric A. , Marek, Kenneth , Mozaffarian, Dariush , Videnovic, Aleksandar , Goetz, Christopher G. , Espay, Alberto J. , Jimenez‐Shahed, Joohi , Friedman, Joseph H. , Litvan, Irene , Chou, Kelvin L. , Bhatti, Danish , Rosenthal, Liana S. , Ahmed, Anwar E. , Saint‐Hilaire, Marie , Shprecher, David , Pahwa, Rajesh , LeWitt, Peter A. , Kaminski, Patricia, Thomas, Karen, Serrano, Carmen , Soileau, Michael J , Schneider, Ruth B. , Waikar, Sushrut S. , Lang, Anthony E. , Mestre, Tiago

Mayo Clinic

JAMA | September 14, 2021 | Volume: 326 | Issue: 10 | Pages: 926

10.1001/jama.2021.10207 | PMID 34519802 Get It

Co-Ordination of Mucosal B Cell and CD8 T Cell Memory by Tissue-Resident CD4 Helper T Cells
Son, Young Min , Son, Y M , Sun, Jie

Mayo Clinic

Cells | September 8, 2021 | Volume: 10 | Issue: 9 | Pages: 2355

10.3390/cells10092355 | PMID 34572004 Get It

Adaptive cellular immunity plays a major role in clearing microbial invasion of mucosal tissues in mammals. Following the clearance of primary pathogens, memory lymphocytes are established both systemically and locally at pathogen entry sites. Recently, resident memory CD8 T and B cells (TRM and BRM respectively), which are parked mainly in non-lymphoid mucosal tissues, were characterized and demonstrated to be essential for protection against secondary microbial invasion. Here we reviewed the current understanding of the cellular and molecular cues regulating CD8 TRM and BRM development, maintenance and function. We focused particularly on elucidating the role of a novel tissue-resident helper T (TRH) cell population in assisting TRM and BRM responses in the respiratory mucosa following viral infection. Finally, we argue that the promotion of TRH responses by future mucosal vaccines would be key to the development of successful universal influenza or coronavirus vaccines, providing long-lasting immunity against a broad spectrum of viral strains.